
Zocdoc is owned by Zocdoc, Inc., a privately held healthcare technology company headquartered in New York City. Founded in 2007 by Cyrus Massoumi, Oliver Kharraz, and Nick Ganju, it operates a marketplace where patients find doctors and book appointments. The company has raised more than $300 million in funding, reached a peak valuation of $1.8 billion, and is led by CEO Oliver Kharraz. It is not publicly traded.
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Zocdoc | Zocdoc, Inc. | Wholly owned |
Zocdoc was founded in New York City in 2007 by Cyrus Massoumi, Oliver Kharraz, and Nick Ganju. Massoumi, a former McKinsey consultant, conceived the idea after a burst eardrum on a flight left him struggling to find a doctor who could see him quickly. The original product was a simple scheduling tool: patients could see doctors' real-time availability and book appointments online instead of calling offices.
The company raised $15 million in Series B funding in 2010 from Founders Fund and Khosla Ventures, capital it used to expand beyond New York. Its original business model charged doctors a flat subscription of roughly $3,000 per year to be listed and bookable on the platform.
Growth accelerated through the mid-2010s. By 2014 Zocdoc had five million monthly users, and a 2015 funding round valued the company at $1.8 billion. But the flat subscription model was breaking down: doctors paid the same fee whether they received one patient or a hundred, which worked in dense early markets but failed as the company expanded to areas where demand was thin. Kharraz has since described the strategy as nearly killing the company.
The board removed Massoumi as CEO in late 2015 and installed Kharraz the following day. Massoumi later sued the company alleging fraud, a case dismissed in 2024. Under Kharraz, Zocdoc spent years rebuilding its business model around per-booking fees of roughly $30 to $140 per new patient, a transition that met resistance from physicians, particularly in New York, its largest market, and involved years of face-to-face provider outreach.
The rebuilt model worked. Zocdoc became profitable, expanded to cover all 50 states, added telehealth during the COVID-19 pandemic, and processed appointment volumes typically fulfilled within 24 to 72 hours of booking. By 2025 the company employed roughly 800 to 1,300 people and was operating profitably without raising new equity capital since 2021.
What is Zocdoc?
Zocdoc is a private healthcare technology company headquartered in New York City. It operates an online marketplace where patients find doctors, verify insurance, and book appointments, with providers paying per new-patient booking.
Who owns Zocdoc?
Zocdoc is owned by its private company Zocdoc, Inc. Ownership is held by founders, employees, and venture investors including Founders Fund and Khosla Ventures. There is no corporate parent.
Is Zocdoc a public company?
No. Zocdoc is privately held and has never listed publicly. It reached a peak valuation of $1.8 billion in 2015 and has not announced IPO plans.
When was Zocdoc founded?
Zocdoc was founded in 2007 in New York City by Cyrus Massoumi, Oliver Kharraz, and Nick Ganju.
How does Zocdoc make money?
Zocdoc charges healthcare providers roughly $30 to $140 for each new patient booking it delivers, plus fees for sponsored placement. Patients use the service free.
Is Zocdoc profitable?
Yes. Following its transition from flat subscriptions to per-booking pricing, Zocdoc reached profitability and has not raised equity capital since February 2021, funding operations from revenue and debt refinancing.
Zocdoc's most significant controversy was internal. The 2015 board removal of co-founder and CEO Cyrus Massoumi produced years of litigation, with Massoumi alleging fraud and improper ouster. The case was dismissed in 2024, closing the dispute.
Externally, the per-booking pricing transition generated provider backlash, including complaints from New York physicians who argued the fees were burdensome, and some lawsuits arose during the rollout period. The company resolved these through extended implementation timelines and direct provider engagement rather than formal regulatory proceedings.
The platform has also faced periodic criticism over the accuracy of insurance coverage listings and provider directory information, a category-wide problem in healthcare directories subject to federal attention on "ghost network" directories. No major regulatory enforcement action against Zocdoc is on record.
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Teladoc Health | United States | 2013 | Mass market | Global | All Genders |
Market Positioning: Zocdoc competes with 1 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Looking for brands with different ownership structures? These similar brands are not owned by Zocdoc, Inc., giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsOwned by Amgen Inc.
Master biotechnology brand of Amgen Inc., the world's largest independent biotech, covering its full portfolio of biologic medicines.
Amgen operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by GoodRx Holdings, Inc.
American healthcare technology platform providing prescription drug price comparison, discount coupons, and telehealth services to help consumers find affordable healthcare options.
GoodRx operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by HCA Healthcare, Inc.
HCA Healthcare is the flagship brand of the largest U.S. for-profit hospital operator, a network of 190 hospitals and about 2,500 ambulatory sites across 19 states and England.
HCA Healthcare operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Pfizer Inc.
American multinational pharmaceutical corporation developing and manufacturing medicines, vaccines, and consumer healthcare products, one of the world's largest pharmaceutical companies.
Pfizer operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Stryker Corporation
Flagship medical technology brand of Stryker Corporation, founded in 1941 and a global leader in orthopaedic implants and surgical equipment.
Stryker operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by ADARx Pharmaceuticals, Inc.
Biotechnology brand of ADARx Pharmaceuticals, the San Diego siRNA company that listed on Nasdaq in September 2026.
ADARx operates independently without a large parent corporation.
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.

Pfizer's respiratory syncytial virus (RSV) vaccine approved for older adults, maternal immunization to protect infants, and younger at-risk adults. Launched 2023.

Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.